期刊文献+

强化他汀治疗对不稳定型心绞痛患者血清超敏C反应蛋白及可溶性CD40配体L的影响 被引量:4

The impact of intensive statin therapy on stability of coronary plaques in unstable angina patients
下载PDF
导出
摘要 目的观察强化他汀治疗不稳定型心绞痛的效果及可能机制。方法将130例不稳定型心绞痛患者随机分为治疗1组(瑞舒伐他汀钙片10 mg,1次/d,50例)、治疗2组(瑞舒伐他汀钙片20 mg,1次/d,50例)和对照组(常规治疗,30例),测定治疗前及治疗后1周、4周、8周时血清超敏C反应蛋白(hs-CRP)、可溶性CD40配体L(sCD40L)、血脂、肝功能等指标,主要心血管事件(MACE)的发生率以及瑞舒伐他汀的药物不良反应情况。结果与对照组相比较,治疗1组和治疗2组治疗后1周、4周、8周血清hs-CRP、sCD40L、LDL-C水平均降低(P<0.05),治疗1组和治疗2组之间治疗后8周hs-CRP、sCD40L差异有统计学意义(P<0.01)。结论不稳定型心绞痛患者强化他汀治疗,可能通过抗炎、改善内皮、稳定斑块等作用而最终获益。 Objective To investigate the clinical effect and significance of intensive statin on serum hs-CRP and soulable CD40L in unstable angina(UA) patients.Methods 130 UA patients were randomly divided into three groups.The control group(n=30) was given the routine medicine,and the other two therapy groups were administered rosuvastatin with 10 mg(group1) or 20 mg(group2) qd for 8 weeks.Levels of serum hs-CRP,sCD40L and lipid,and the incidences of major adverse cardiovascular events were determined before and after treatment.Results Compared with the control group,the levels of serum hs-CRP,CD40L,LDL-C and the rate of angina attacks were significantly decreased in treatment group 1 and group 2(n=50,P0.05).There was significant difference between group1 ang group2(P0.01).Conclusion Intensive treatment of rosuvastatin is beneficial for UA patients.The possible mechanisms include anti-inflammation,improving the endothelium and stabilizing of plaque.
出处 《中国临床保健杂志》 CAS 2012年第2期147-149,共3页 Chinese Journal of Clinical Healthcare
关键词 心绞痛 不稳定型 C反应蛋白质 CD40配体 Angina unstable C-reactive protein CD40 ligand
  • 相关文献

参考文献15

二级参考文献48

  • 1刘海波,高润霖,陈在嘉,姚康宝,陈纪林,杨跃进,乔树宾,徐义枢.不稳定性心绞痛患者冠状动脉造影形态学特点及其意义[J].中国循环杂志,1996,11(1):3-5. 被引量:32
  • 2[1]Jones P,Kafonek S,Laurora I,et al.Comparative dose efficacy study of atorvastatin versus simvastatin,lovstatin,and fluvastatin in patients with hypercholesterolemia (the CURVES study)[J].Am J Cardiol,1998,81:582-587.
  • 3[2]Jones PH,Mckenney JM,Karalis DG,et al.Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia[ J ].Am Heart J,2005,149:e1.
  • 4[3]Andrens TC,Ballantyne CM,Hsia JA,et al.Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins[ J].Am J Med,2001,111:185-191.
  • 5[4]Newman CB,Palmer G,Silbershatz H,et al.Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients[ J].Am J Cardiol,2003,92:670-676.
  • 6[5]Ferrier KE,Muhlmann MH,Baguet JP,et al.Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertensions[ J].J Am Coll Cardiol,2002,39:1020-1025.
  • 7[6]Athyros VG,Mikhailidis DP,Papageorgiou AA,et al.The effect of statins versus untreated dyslipidemia on renal function in patients with coronary heart disease,A subgroup analysis of the Greek atovastatin and coronary heart disease evaluation (GREACE) study[ J ].J Clin Pathol,2004,57:728-734.
  • 8[7]Strandberg TE,Vanhanen H,Tikkanen MJ,et al.Effect of statins on C-reactive protein in patients with coronary heart disease[J].Lancet,1999,353:118-119.
  • 9[8]Schwartz GG,Olsson AG,Ezekowitz MD,et al.Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes:the MIRACL study:A randomized controlled trial[J].JAMA,2001,285:1711-1718.
  • 10[9]Nissen SE,Tuzcu EM,Schoenhagen P,et al.Effect of intensive compare with moderate lipid-lowering therapy on progression of coronary atherosclerosis:a randomized controlled trial[ J].JAMA,2004,291:1071-1080.

共引文献70

同被引文献31

二级引证文献38

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部